On Wednesday 22 June, prof.dr. Maureen Rutten-van Mölken presented the Position Paper 'Personalised Medicine from a Health Economic Perspective - Lessons Learned and Potential Opportunities Ahead' during the third ICPerMed workshop in Brussels.
Personalised Medicine (PM) – is essential for improving the effectiveness of many public health and healthcare interventions as it overcomes the current limited approach of ‘one-size-fits-all’ and the unhelpful notion of the ‘average’ individual.
Maureen's workshop provides important input for the ‘European Partnership on Personalised Medicine’, which is being established by the European Commission. The steps already taken and future steps towards this new initiative are described here.
What is Personalised Medicine?
There are several definitions for personalised medicine. HEcoPerMed uses the following definition: “It is widely understood that personalised medicine refers to a medical model using characterisation of individuals’ phenotypes and genotypes (e.g., molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention.”
Download Position Paper
- Professor
